Compass Pathways may be the first to benefit from an accelerated approval process.

Compass Pathways stock surged Monday after President Donald Trump signed an executive order tied to psychedelic drugs.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.

The field of psychedelic medicine is relatively new, and because of this, certain investors consider it to be loaded with potential. That's why even minor events in companies specializing in this can be greeted with notable share price pops. Compass ...

Compass Pathways plc (NASDAQ:CMPS) released data from the Phase 3 COMP005 trial, the first of two Phase 3 trials evaluating COMP360 for treatment-resistant depression (TRD). Despite meeting the primary endpoint, the company’s stock experienced a ...

Shares of Compass Pathways fell after the company recorded a wider-than-expected fourth-quarter loss. Shares were down 3.3% to $5.17 in Tuesday morning trading. The stock is up 66% over the past year.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.

Wall Street is currently pivoting toward high-growth biotech plays as federal support accelerates a revolution in alternative medicine.

President Trump's executive order is giving psychedelic stocks a boost. These companies are leaders in the industry.

Towards that end in 2018, it received FDA's Breakthrough Therapy designation for COMP360 in the treatment of TRD. In 11/2021 it announced positive results from its phase 2b trial which was written up in an 11/2022 article in NEJM. In 2025, it commenced a pivotal trial program for COMP360. It consisted of: